Global (United States, European Union and China) Impetigo Drug
Global (United States, European Union and China) Impetigo Drug

Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Players and Region - Global Market Outlook to 2026

Impetigo Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 241 Pages 173 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Impetigo Drug Market?

Impetigo, also known as impetigo contagiosa or pyoderma, is a bacterial skin infection that is highly contagious by nature. It is considered to be one of the most common skin diseases around the world. Cases of infection in adults are rare, but minors and adolescents are more prone to the disease. In addition, people who engage in close physical contact sports such as wrestling, rugby, and American football are prone to the disease regardless of age. Impetigo is a common skin disease that infects nearly two percent of the world's population. Symptoms of impetigo include initial blisters with red bumps, sores on the skin, mostly on the face. However, in later stages, they can also be developed by other parts of the body such as the legs and arms. The blisters that appear on the skin can be irritating or sometimes painful. The wounds are mostly filled with pus that forms scabs. When scratching, the infection can spread to other areas of the skin. In addition, the likelihood of infection is higher in warm and humid conditions. Impetigo is one of the most common bacterial skin diseases and the need for medication is significantly high. The increasing incidence of the disease in recent years is favoring the global market for impetigo therapeutics. In addition, the number of minors and toddlers is increasing and is expected to have a positive impact on overall market growth. In addition, increasing awareness and low treatment costs are expected to drive the market in the coming years. For example, the introduction of improved versions of mupirocin, synthetic peptides, and ozenoxacin at a reasonable price range will benefit overall market growth.

The market study is being classified by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin and Others) and major geographies with country level break-up.

Destiny Pharma Ltd. (United Kingdom), Foamix Pharmaceuticals Ltd. (United States), Orchid Chemicals & Pharmaceuticals (India), Roche Holding AG (Switzerland), Laboratories Ojer Pharma SL (Spain), Lytix Biopharma AS (Norway), Cutanea Life Sciences (United States), GlaxoSmithKline (United Kingdom), NovaBay Pharmaceuticals (United States), LEO Pharma (Denmark) and Medimetriks Pharmaceuticals (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Impetigo Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Impetigo Drug market by Type, Application and Region.

On the basis of geography, the market of Impetigo Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Incidence of the Disease
  • Increasing Awareness and Low Cost Of Treatment
  • The Rising Population of Minors and Infants

Market Trend
  • The Introduction of Improved Versions of Mupirocin, Synthetic Peptides and Ozenoxacin at a Reasonable Price Range
  • The Growing Healthcare Infrastructure

Restraints
  • The Risk of Side Effects Caused By Several Medicines and Drug

Opportunities
  • Increase in Healthcare Expenditure
  • Rising Research and Development of Novel Therapeutic Drugs

Challenges
  • Limited Options of Advanced Medication and Therapeutics





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Impetigo Drug, Suppliers and Distributors of Impetigo Drug, Venture Capitalists and Private Equity Firms and End-Use Industry

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Impetigo Drug Market?
"Increasing Incidence of the Disease " is seen as one of major growth factors of Impetigo Drug Market in years to come.

2. Can we have customized study for Impetigo Drug Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Report Objectives / Segmentation Covered
By Type
  • FMX-102
  • LTX-109
  • Mupirocin
  • Ozenoxacin
  • Others
By Route of Administration
  • Topical
  • Oral

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of the Disease
      • 3.2.2. Increasing Awareness and Low Cost Of Treatment
      • 3.2.3. The Rising Population of Minors and Infants
    • 3.3. Market Challenges
      • 3.3.1. Limited Options of Advanced Medication and Therapeutics
    • 3.4. Market Trends
      • 3.4.1. The Introduction of Improved Versions of Mupirocin, Synthetic Peptides and Ozenoxacin at a Reasonable Price Range
      • 3.4.2. The Growing Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Impetigo Drug, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Impetigo Drug (Value)
      • 5.2.1. Global Impetigo Drug by: Type (Value)
        • 5.2.1.1. FMX-102
        • 5.2.1.2. LTX-109
        • 5.2.1.3. Mupirocin
        • 5.2.1.4. Ozenoxacin
        • 5.2.1.5. Others
      • 5.2.2. Global Impetigo Drug by: Route of Administration (Value)
        • 5.2.2.1. Topical
        • 5.2.2.2. Oral
      • 5.2.3. Global Impetigo Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Pharmacy
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Impetigo Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Impetigo Drug (Volume)
      • 5.3.1. Global Impetigo Drug by: Type (Volume)
        • 5.3.1.1. FMX-102
        • 5.3.1.2. LTX-109
        • 5.3.1.3. Mupirocin
        • 5.3.1.4. Ozenoxacin
        • 5.3.1.5. Others
      • 5.3.2. Global Impetigo Drug by: Route of Administration (Volume)
        • 5.3.2.1. Topical
        • 5.3.2.2. Oral
      • 5.3.3. Global Impetigo Drug by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacy
        • 5.3.3.2. Online Pharmacy
        • 5.3.3.3. Retail Pharmacy
      • 5.3.4. Global Impetigo Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Impetigo Drug (Price)
      • 5.4.1. Global Impetigo Drug by: Type (Price)
  • 6. Impetigo Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Destiny Pharma Ltd. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Foamix Pharmaceuticals Ltd. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Orchid Chemicals & Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Laboratories Ojer Pharma SL (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lytix Biopharma AS (Norway)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cutanea Life Sciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. NovaBay Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. LEO Pharma (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Medimetriks Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Impetigo Drug Sale, by Type, Route of Administration, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Impetigo Drug (Value)
      • 7.2.1. Global Impetigo Drug by: Type (Value)
        • 7.2.1.1. FMX-102
        • 7.2.1.2. LTX-109
        • 7.2.1.3. Mupirocin
        • 7.2.1.4. Ozenoxacin
        • 7.2.1.5. Others
      • 7.2.2. Global Impetigo Drug by: Route of Administration (Value)
        • 7.2.2.1. Topical
        • 7.2.2.2. Oral
      • 7.2.3. Global Impetigo Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Pharmacy
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Impetigo Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Impetigo Drug (Volume)
      • 7.3.1. Global Impetigo Drug by: Type (Volume)
        • 7.3.1.1. FMX-102
        • 7.3.1.2. LTX-109
        • 7.3.1.3. Mupirocin
        • 7.3.1.4. Ozenoxacin
        • 7.3.1.5. Others
      • 7.3.2. Global Impetigo Drug by: Route of Administration (Volume)
        • 7.3.2.1. Topical
        • 7.3.2.2. Oral
      • 7.3.3. Global Impetigo Drug by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacy
        • 7.3.3.2. Online Pharmacy
        • 7.3.3.3. Retail Pharmacy
      • 7.3.4. Global Impetigo Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Impetigo Drug (Price)
      • 7.4.1. Global Impetigo Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Impetigo Drug: by Type(USD Million)
  • Table 2. Impetigo Drug FMX-102 , by Region USD Million (2015-2020)
  • Table 3. Impetigo Drug LTX-109 , by Region USD Million (2015-2020)
  • Table 4. Impetigo Drug Mupirocin , by Region USD Million (2015-2020)
  • Table 5. Impetigo Drug Ozenoxacin , by Region USD Million (2015-2020)
  • Table 6. Impetigo Drug Others , by Region USD Million (2015-2020)
  • Table 7. Impetigo Drug: by Route of Administration(USD Million)
  • Table 8. Impetigo Drug Topical , by Region USD Million (2015-2020)
  • Table 9. Impetigo Drug Oral , by Region USD Million (2015-2020)
  • Table 10. Impetigo Drug: by Distribution Channel(USD Million)
  • Table 11. Impetigo Drug Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 12. Impetigo Drug Online Pharmacy , by Region USD Million (2015-2020)
  • Table 13. Impetigo Drug Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 14. South America Impetigo Drug, by Country USD Million (2015-2020)
  • Table 15. South America Impetigo Drug, by Type USD Million (2015-2020)
  • Table 16. South America Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 17. South America Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Impetigo Drug, by Type USD Million (2015-2020)
  • Table 19. Brazil Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 20. Brazil Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Impetigo Drug, by Type USD Million (2015-2020)
  • Table 22. Argentina Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 23. Argentina Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Impetigo Drug, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 26. Rest of South America Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Impetigo Drug, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Impetigo Drug, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 30. Asia Pacific Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Impetigo Drug, by Type USD Million (2015-2020)
  • Table 32. China Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 33. China Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Impetigo Drug, by Type USD Million (2015-2020)
  • Table 35. Japan Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 36. Japan Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Impetigo Drug, by Type USD Million (2015-2020)
  • Table 38. India Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 39. India Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Impetigo Drug, by Type USD Million (2015-2020)
  • Table 41. South Korea Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 42. South Korea Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Impetigo Drug, by Type USD Million (2015-2020)
  • Table 44. Taiwan Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 45. Taiwan Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Impetigo Drug, by Type USD Million (2015-2020)
  • Table 47. Australia Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 48. Australia Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Impetigo Drug, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Impetigo Drug, by Country USD Million (2015-2020)
  • Table 53. Europe Impetigo Drug, by Type USD Million (2015-2020)
  • Table 54. Europe Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 55. Europe Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Impetigo Drug, by Type USD Million (2015-2020)
  • Table 57. Germany Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 58. Germany Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Impetigo Drug, by Type USD Million (2015-2020)
  • Table 60. France Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 61. France Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Impetigo Drug, by Type USD Million (2015-2020)
  • Table 63. Italy Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 64. Italy Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Impetigo Drug, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 67. United Kingdom Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Impetigo Drug, by Type USD Million (2015-2020)
  • Table 69. Netherlands Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 70. Netherlands Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Impetigo Drug, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 73. Rest of Europe Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Impetigo Drug, by Country USD Million (2015-2020)
  • Table 75. MEA Impetigo Drug, by Type USD Million (2015-2020)
  • Table 76. MEA Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 77. MEA Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Impetigo Drug, by Type USD Million (2015-2020)
  • Table 79. Middle East Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 80. Middle East Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Impetigo Drug, by Type USD Million (2015-2020)
  • Table 82. Africa Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 83. Africa Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Impetigo Drug, by Country USD Million (2015-2020)
  • Table 85. North America Impetigo Drug, by Type USD Million (2015-2020)
  • Table 86. North America Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 87. North America Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Impetigo Drug, by Type USD Million (2015-2020)
  • Table 89. United States Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 90. United States Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Impetigo Drug, by Type USD Million (2015-2020)
  • Table 92. Canada Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 93. Canada Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Impetigo Drug, by Type USD Million (2015-2020)
  • Table 95. Mexico Impetigo Drug, by Route of Administration USD Million (2015-2020)
  • Table 96. Mexico Impetigo Drug, by Distribution Channel USD Million (2015-2020)
  • Table 97. Impetigo Drug Sales: by Type(K Tons)
  • Table 98. Impetigo Drug Sales FMX-102 , by Region K Tons (2015-2020)
  • Table 99. Impetigo Drug Sales LTX-109 , by Region K Tons (2015-2020)
  • Table 100. Impetigo Drug Sales Mupirocin , by Region K Tons (2015-2020)
  • Table 101. Impetigo Drug Sales Ozenoxacin , by Region K Tons (2015-2020)
  • Table 102. Impetigo Drug Sales Others , by Region K Tons (2015-2020)
  • Table 103. Impetigo Drug Sales: by Route of Administration(K Tons)
  • Table 104. Impetigo Drug Sales Topical , by Region K Tons (2015-2020)
  • Table 105. Impetigo Drug Sales Oral , by Region K Tons (2015-2020)
  • Table 106. Impetigo Drug Sales: by Distribution Channel(K Tons)
  • Table 107. Impetigo Drug Sales Hospital Pharmacy , by Region K Tons (2015-2020)
  • Table 108. Impetigo Drug Sales Online Pharmacy , by Region K Tons (2015-2020)
  • Table 109. Impetigo Drug Sales Retail Pharmacy , by Region K Tons (2015-2020)
  • Table 110. South America Impetigo Drug Sales, by Country K Tons (2015-2020)
  • Table 111. South America Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 112. South America Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 113. South America Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 114. Brazil Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 115. Brazil Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 116. Brazil Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 117. Argentina Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 118. Argentina Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 119. Argentina Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 120. Rest of South America Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 121. Rest of South America Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 122. Rest of South America Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 123. Asia Pacific Impetigo Drug Sales, by Country K Tons (2015-2020)
  • Table 124. Asia Pacific Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 125. Asia Pacific Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 126. Asia Pacific Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 127. China Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 128. China Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 129. China Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 130. Japan Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 131. Japan Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 132. Japan Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 133. India Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 134. India Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 135. India Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 136. South Korea Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 137. South Korea Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 138. South Korea Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 139. Taiwan Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 140. Taiwan Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 141. Taiwan Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 142. Australia Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 143. Australia Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 144. Australia Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 145. Rest of Asia-Pacific Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 146. Rest of Asia-Pacific Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 147. Rest of Asia-Pacific Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 148. Europe Impetigo Drug Sales, by Country K Tons (2015-2020)
  • Table 149. Europe Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 150. Europe Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 151. Europe Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 152. Germany Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 153. Germany Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 154. Germany Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 155. France Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 156. France Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 157. France Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 158. Italy Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 159. Italy Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 160. Italy Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 161. United Kingdom Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 162. United Kingdom Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 163. United Kingdom Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 164. Netherlands Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 165. Netherlands Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 166. Netherlands Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 167. Rest of Europe Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 168. Rest of Europe Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 169. Rest of Europe Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. MEA Impetigo Drug Sales, by Country K Tons (2015-2020)
  • Table 171. MEA Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 172. MEA Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 173. MEA Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. Middle East Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 175. Middle East Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 176. Middle East Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 177. Africa Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 178. Africa Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 179. Africa Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 180. North America Impetigo Drug Sales, by Country K Tons (2015-2020)
  • Table 181. North America Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 182. North America Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 183. North America Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 184. United States Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 185. United States Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 186. United States Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 187. Canada Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 188. Canada Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 189. Canada Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 190. Mexico Impetigo Drug Sales, by Type K Tons (2015-2020)
  • Table 191. Mexico Impetigo Drug Sales, by Route of Administration K Tons (2015-2020)
  • Table 192. Mexico Impetigo Drug Sales, by Distribution Channel K Tons (2015-2020)
  • Table 193. Impetigo Drug: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Impetigo Drug: by Type(USD Million)
  • Table 206. Impetigo Drug FMX-102 , by Region USD Million (2021-2026)
  • Table 207. Impetigo Drug LTX-109 , by Region USD Million (2021-2026)
  • Table 208. Impetigo Drug Mupirocin , by Region USD Million (2021-2026)
  • Table 209. Impetigo Drug Ozenoxacin , by Region USD Million (2021-2026)
  • Table 210. Impetigo Drug Others , by Region USD Million (2021-2026)
  • Table 211. Impetigo Drug: by Route of Administration(USD Million)
  • Table 212. Impetigo Drug Topical , by Region USD Million (2021-2026)
  • Table 213. Impetigo Drug Oral , by Region USD Million (2021-2026)
  • Table 214. Impetigo Drug: by Distribution Channel(USD Million)
  • Table 215. Impetigo Drug Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 216. Impetigo Drug Online Pharmacy , by Region USD Million (2021-2026)
  • Table 217. Impetigo Drug Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 218. South America Impetigo Drug, by Country USD Million (2021-2026)
  • Table 219. South America Impetigo Drug, by Type USD Million (2021-2026)
  • Table 220. South America Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 221. South America Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 222. Brazil Impetigo Drug, by Type USD Million (2021-2026)
  • Table 223. Brazil Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 224. Brazil Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 225. Argentina Impetigo Drug, by Type USD Million (2021-2026)
  • Table 226. Argentina Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 227. Argentina Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 228. Rest of South America Impetigo Drug, by Type USD Million (2021-2026)
  • Table 229. Rest of South America Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 230. Rest of South America Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 231. Asia Pacific Impetigo Drug, by Country USD Million (2021-2026)
  • Table 232. Asia Pacific Impetigo Drug, by Type USD Million (2021-2026)
  • Table 233. Asia Pacific Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 234. Asia Pacific Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 235. China Impetigo Drug, by Type USD Million (2021-2026)
  • Table 236. China Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 237. China Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 238. Japan Impetigo Drug, by Type USD Million (2021-2026)
  • Table 239. Japan Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 240. Japan Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 241. India Impetigo Drug, by Type USD Million (2021-2026)
  • Table 242. India Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 243. India Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 244. South Korea Impetigo Drug, by Type USD Million (2021-2026)
  • Table 245. South Korea Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 246. South Korea Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 247. Taiwan Impetigo Drug, by Type USD Million (2021-2026)
  • Table 248. Taiwan Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 249. Taiwan Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 250. Australia Impetigo Drug, by Type USD Million (2021-2026)
  • Table 251. Australia Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 252. Australia Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Impetigo Drug, by Type USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 256. Europe Impetigo Drug, by Country USD Million (2021-2026)
  • Table 257. Europe Impetigo Drug, by Type USD Million (2021-2026)
  • Table 258. Europe Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 259. Europe Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 260. Germany Impetigo Drug, by Type USD Million (2021-2026)
  • Table 261. Germany Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 262. Germany Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 263. France Impetigo Drug, by Type USD Million (2021-2026)
  • Table 264. France Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 265. France Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 266. Italy Impetigo Drug, by Type USD Million (2021-2026)
  • Table 267. Italy Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 268. Italy Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 269. United Kingdom Impetigo Drug, by Type USD Million (2021-2026)
  • Table 270. United Kingdom Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 271. United Kingdom Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 272. Netherlands Impetigo Drug, by Type USD Million (2021-2026)
  • Table 273. Netherlands Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 274. Netherlands Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 275. Rest of Europe Impetigo Drug, by Type USD Million (2021-2026)
  • Table 276. Rest of Europe Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 277. Rest of Europe Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 278. MEA Impetigo Drug, by Country USD Million (2021-2026)
  • Table 279. MEA Impetigo Drug, by Type USD Million (2021-2026)
  • Table 280. MEA Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 281. MEA Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 282. Middle East Impetigo Drug, by Type USD Million (2021-2026)
  • Table 283. Middle East Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 284. Middle East Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 285. Africa Impetigo Drug, by Type USD Million (2021-2026)
  • Table 286. Africa Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 287. Africa Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 288. North America Impetigo Drug, by Country USD Million (2021-2026)
  • Table 289. North America Impetigo Drug, by Type USD Million (2021-2026)
  • Table 290. North America Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 291. North America Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 292. United States Impetigo Drug, by Type USD Million (2021-2026)
  • Table 293. United States Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 294. United States Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 295. Canada Impetigo Drug, by Type USD Million (2021-2026)
  • Table 296. Canada Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 297. Canada Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 298. Mexico Impetigo Drug, by Type USD Million (2021-2026)
  • Table 299. Mexico Impetigo Drug, by Route of Administration USD Million (2021-2026)
  • Table 300. Mexico Impetigo Drug, by Distribution Channel USD Million (2021-2026)
  • Table 301. Impetigo Drug Sales: by Type(K Tons)
  • Table 302. Impetigo Drug Sales FMX-102 , by Region K Tons (2021-2026)
  • Table 303. Impetigo Drug Sales LTX-109 , by Region K Tons (2021-2026)
  • Table 304. Impetigo Drug Sales Mupirocin , by Region K Tons (2021-2026)
  • Table 305. Impetigo Drug Sales Ozenoxacin , by Region K Tons (2021-2026)
  • Table 306. Impetigo Drug Sales Others , by Region K Tons (2021-2026)
  • Table 307. Impetigo Drug Sales: by Route of Administration(K Tons)
  • Table 308. Impetigo Drug Sales Topical , by Region K Tons (2021-2026)
  • Table 309. Impetigo Drug Sales Oral , by Region K Tons (2021-2026)
  • Table 310. Impetigo Drug Sales: by Distribution Channel(K Tons)
  • Table 311. Impetigo Drug Sales Hospital Pharmacy , by Region K Tons (2021-2026)
  • Table 312. Impetigo Drug Sales Online Pharmacy , by Region K Tons (2021-2026)
  • Table 313. Impetigo Drug Sales Retail Pharmacy , by Region K Tons (2021-2026)
  • Table 314. South America Impetigo Drug Sales, by Country K Tons (2021-2026)
  • Table 315. South America Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 316. South America Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 317. South America Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 318. Brazil Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 319. Brazil Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 320. Brazil Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 321. Argentina Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 322. Argentina Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 323. Argentina Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 324. Rest of South America Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 325. Rest of South America Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 326. Rest of South America Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 327. Asia Pacific Impetigo Drug Sales, by Country K Tons (2021-2026)
  • Table 328. Asia Pacific Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 329. Asia Pacific Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 330. Asia Pacific Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 331. China Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 332. China Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 333. China Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 334. Japan Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 335. Japan Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 336. Japan Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 337. India Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 338. India Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 339. India Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 340. South Korea Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 341. South Korea Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 342. South Korea Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 343. Taiwan Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 344. Taiwan Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 345. Taiwan Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 346. Australia Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 347. Australia Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 348. Australia Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 349. Rest of Asia-Pacific Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 350. Rest of Asia-Pacific Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 351. Rest of Asia-Pacific Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 352. Europe Impetigo Drug Sales, by Country K Tons (2021-2026)
  • Table 353. Europe Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 354. Europe Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 355. Europe Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 356. Germany Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 357. Germany Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 358. Germany Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 359. France Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 360. France Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 361. France Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 362. Italy Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 363. Italy Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 364. Italy Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 365. United Kingdom Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 366. United Kingdom Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 367. United Kingdom Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 368. Netherlands Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 369. Netherlands Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 370. Netherlands Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 371. Rest of Europe Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 372. Rest of Europe Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 373. Rest of Europe Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 374. MEA Impetigo Drug Sales, by Country K Tons (2021-2026)
  • Table 375. MEA Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 376. MEA Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 377. MEA Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 378. Middle East Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 379. Middle East Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 380. Middle East Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 381. Africa Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 382. Africa Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 383. Africa Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 384. North America Impetigo Drug Sales, by Country K Tons (2021-2026)
  • Table 385. North America Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 386. North America Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 387. North America Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 388. United States Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 389. United States Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 390. United States Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 391. Canada Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 392. Canada Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 393. Canada Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 394. Mexico Impetigo Drug Sales, by Type K Tons (2021-2026)
  • Table 395. Mexico Impetigo Drug Sales, by Route of Administration K Tons (2021-2026)
  • Table 396. Mexico Impetigo Drug Sales, by Distribution Channel K Tons (2021-2026)
  • Table 397. Impetigo Drug: by Type(USD/Units)
  • Table 398. Research Programs/Design for This Report
  • Table 399. Key Data Information from Secondary Sources
  • Table 400. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Impetigo Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Impetigo Drug: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Impetigo Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Impetigo Drug Share (%), by Country
  • Figure 8. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 9. Europe Impetigo Drug Share (%), by Country
  • Figure 10. MEA Impetigo Drug Share (%), by Country
  • Figure 11. North America Impetigo Drug Share (%), by Country
  • Figure 12. Global Impetigo Drug: by Type K Tons (2015-2020)
  • Figure 13. Global Impetigo Drug: by Route of Administration K Tons (2015-2020)
  • Figure 14. Global Impetigo Drug: by Distribution Channel K Tons (2015-2020)
  • Figure 15. South America Impetigo Drug Share (%), by Country
  • Figure 16. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 17. Europe Impetigo Drug Share (%), by Country
  • Figure 18. MEA Impetigo Drug Share (%), by Country
  • Figure 19. North America Impetigo Drug Share (%), by Country
  • Figure 20. Global Impetigo Drug: by Type USD/Units (2015-2020)
  • Figure 21. Global Impetigo Drug share by Players 2020 (%)
  • Figure 22. Global Impetigo Drug share by Players (Top 3) 2020(%)
  • Figure 23. Global Impetigo Drug share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Destiny Pharma Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Destiny Pharma Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Foamix Pharmaceuticals Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Foamix Pharmaceuticals Ltd. (United States) Revenue: by Geography 2020
  • Figure 29. Orchid Chemicals & Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 30. Orchid Chemicals & Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Laboratories Ojer Pharma SL (Spain) Revenue, Net Income and Gross profit
  • Figure 34. Laboratories Ojer Pharma SL (Spain) Revenue: by Geography 2020
  • Figure 35. Lytix Biopharma AS (Norway) Revenue, Net Income and Gross profit
  • Figure 36. Lytix Biopharma AS (Norway) Revenue: by Geography 2020
  • Figure 37. Cutanea Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 38. Cutanea Life Sciences (United States) Revenue: by Geography 2020
  • Figure 39. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 41. NovaBay Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 42. NovaBay Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 43. LEO Pharma (Denmark) Revenue, Net Income and Gross profit
  • Figure 44. LEO Pharma (Denmark) Revenue: by Geography 2020
  • Figure 45. Medimetriks Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 46. Medimetriks Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 47. Global Impetigo Drug: by Type USD Million (2021-2026)
  • Figure 48. Global Impetigo Drug: by Route of Administration USD Million (2021-2026)
  • Figure 49. Global Impetigo Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 50. South America Impetigo Drug Share (%), by Country
  • Figure 51. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 52. Europe Impetigo Drug Share (%), by Country
  • Figure 53. MEA Impetigo Drug Share (%), by Country
  • Figure 54. North America Impetigo Drug Share (%), by Country
  • Figure 55. Global Impetigo Drug: by Type K Tons (2021-2026)
  • Figure 56. Global Impetigo Drug: by Route of Administration K Tons (2021-2026)
  • Figure 57. Global Impetigo Drug: by Distribution Channel K Tons (2021-2026)
  • Figure 58. South America Impetigo Drug Share (%), by Country
  • Figure 59. Asia Pacific Impetigo Drug Share (%), by Country
  • Figure 60. Europe Impetigo Drug Share (%), by Country
  • Figure 61. MEA Impetigo Drug Share (%), by Country
  • Figure 62. North America Impetigo Drug Share (%), by Country
  • Figure 63. Global Impetigo Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Destiny Pharma Ltd. (United Kingdom)
  • Foamix Pharmaceuticals Ltd. (United States)
  • Orchid Chemicals & Pharmaceuticals (India)
  • Roche Holding AG (Switzerland)
  • Laboratories Ojer Pharma SL (Spain)
  • Lytix Biopharma AS (Norway)
  • Cutanea Life Sciences (United States)
  • GlaxoSmithKline (United Kingdom)
  • NovaBay Pharmaceuticals (United States)
  • LEO Pharma (Denmark)
  • Medimetriks Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation